BeiGene to acquire global license to Ensem Therapeutics’ CDK2 inhibitor
The oral CDK2 inhibitor from Ensem is an investigational new drug (IND) application-ready asset. BeiGene R&D global head Lai Wang said: “We are committed to developing novel molecules